Cross-institution positioning
May 15, 2026Accumulation leaning. 1 accumulating across 1 comparable institution.
Source: Schedule 13 researchMPLT Institutional Ownership
MapLight Therapeutics, Inc.
Latest stored close $8.83 as of Oct 9, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
56/100
1 tracked · 1 comparable
Latest filing
May 15, 2026
Positive breadth
1 positive · 0 negative
Recent close
$8.83
Research confidence
Limited
Institutional Research 68/100 · 1 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing May 15, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating1
Newly reported0
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 56/100
Confidence:Limited
Why this signal
- 1 tracked institution accumulating versus 0 reducing/exited.
Conflicting evidence
- Institutions are bullish while comparable SEC fundamentals are deteriorating.
Institutional
64/100
Insiders
53/100
Fundamentals
30/100
Events
50/100
Quarterly 13F activity
Jun 30, 20261 increased/new, 1 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Sep 16, 2026Over the last 90 days, SEC-coded non-derivative P/S activity includes 6 purchases by 2 reporting owners and 46 sales by 6 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Sep 23, 20264 non-amendment material events in the last 90 days; 3 capital-related filing/events (1 equity-related, 0 debt-related); Latest classified evidence: Prospectus filing. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 13, 2026Net income -101.7% YoY; Free cash flow -61.3% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 10% through its reported 52-week range.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Schedule 13G amendment from T. Rowe Price Investment Management.
Filed May 15, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
May 15, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
T. Rowe Price Investment Management
Filed May 15, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
T. Rowe Price Investment Management
Filed May 15, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales11 reporting owner(s)
90-day purchase breadth2Multi-insider
90-day sale breadth6Multi-insider
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Hanson Kristopher | SOpen-market or private sale | Voting Common Stock | 16.5K | $11.67 | Direct | Sep 18, 2026 |
| Aug 17, 2026 | Kroeger Christopher A. | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 94.0K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Kroeger Christopher A. | AGrant, award, or other acquisition | Voting Common Stock | 23.1K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Foff Erin Pennock | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 54.2K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Foff Erin Pennock | AGrant, award, or other acquisition | Voting Common Stock | 13.4K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Hanson Kristopher | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 31.4K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Hanson Kristopher | AGrant, award, or other acquisition | Voting Common Stock | 7.7K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Lillie James Woodruff | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 31.4K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Lillie James Woodruff | AGrant, award, or other acquisition | Voting Common Stock | 7.7K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | GILLIS JONATHAN | AGrant, award, or other acquisition · derivative | Employee Stock Option (Right to Buy) | 2.8K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | GILLIS JONATHAN | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 24.5K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | GILLIS JONATHAN | AGrant, award, or other acquisition | Voting Common Stock | 2.2K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | GILLIS JONATHAN | AGrant, award, or other acquisition | Voting Common Stock | 6.0K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Kreitzer Anatol | AGrant, award, or other acquisition · derivative | Employee Stock Option (right to buy) | 24.5K | $0.00 | Direct | Aug 19, 2026 |
| Aug 17, 2026 | Kreitzer Anatol | AGrant, award, or other acquisition | Voting Common Stock | 6.0K | $0.00 | Direct | Aug 19, 2026 |
| Aug 14, 2026 | Catalyst4, Inc. | POpen-market or private purchase · derivative | Warrants (right to buy) | 2.9M | $11.38 | Indirect | Aug 18, 2026 |
| Aug 14, 2026 | Catalyst4, Inc. | POpen-market or private purchase | Voting Common Stock | 4.4M | $11.38 | Indirect | Aug 18, 2026 |
| Aug 3, 2026 | Lillie James Woodruff | SOpen-market or private sale | Voting Common Stock | 22.1K | $12.54 | Direct | Aug 4, 2026 |
| Jul 30, 2026 | Catalyst4, Inc. | POpen-market or private purchase | Voting Common Stock | 1.0M | $13.00 | Indirect | Jul 30, 2026 |
| Jul 29, 2026 | Catalyst4, Inc. | POpen-market or private purchase | Voting Common Stock | 3.0K | $12.63 | Indirect | Jul 30, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events2
90-day capital-related3
90-day equity-related1
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 23, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
| Sep 18, 2026 | S-1/AAmendment | — | Securities registration statement | Capital-related | Filing |
| Sep 9, 2026 | S-1 | — | Securities registration statement | Capital-related | Filing |
| Aug 13, 2026 | 8-K | 1.01, 2.02, 3.02, 7.01, 9.01 | Material definitive agreement; Results of operations / financial condition; Unregistered sale of equity securities; Regulation FD disclosure; Financial statements / exhibits | Equity | Filing |
| Jul 27, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jun 24, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| Jun 22, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jun 18, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| May 14, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Apr 29, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Mar 26, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Mar 26, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Operating income
$-63.5M
Q2 2026
-107.2% YoY 10-Q filed Aug 13, 2026
Net income
$-60.2M
Q2 2026
-101.7% YoY 10-Q filed Aug 13, 2026
Diluted EPS
$-1.32
Q2 2026
+96.6% YoY 10-Q filed Aug 13, 2026
Operating cash flow
$-96.0M
YTD through Jun 30, 2026
-61.4% YoY 10-Q filed Aug 13, 2026
Free cash flow
$-96.1M
YTD through Jun 30, 2026
-61.3% YoY 10-Q filed Aug 13, 2026
Cash & equivalents
$71.6M
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Assets
$368.3M
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Liabilities
$20.0M
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Stockholders’ equity
$348.3M
As of Jun 30, 2026
+242.1% YoY 10-Q filed Aug 13, 2026
Shares outstanding
42.4M
As of Mar 19, 2026
10-K filed Mar 26, 2026
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$12.08
View live quote ↗
52-week low
$9.10
Jul 28, 2026
52-week high
$40.43
Jul 10, 2026
Below 52-week high
70.1%
1W return
-13.4%
1M return
+2.8%
3M return
-56.8%
6M return
-36.7%
YTD return
-31.2%
1Y return
30-day volatility
66.4%
90-day volatility
235.4%
1Y max drawdown
-75.1%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 3 of 3 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment | Reported accumulation | 3.1M +338.4K | 12.00% 0.00 pts | $20.33 | $28.73 | $8.83 |
| T. Rowe Price Investment Management CIK0001897612 | Dec 31, 2025 quarter end Feb 19, 2026 filed Amended Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 2.8M | $8.83 | |||
| T. Rowe Price Investment Management CIK0001897612 | Dec 31, 2025 observed Feb 17, 2026 filed · 48d Initial Schedule 13G | Initial Schedule 13G | 2.8M | 12.00% | $17.57 | $17.25 | $8.83 |
Explore more institutional activity
Related research
Compare MPLT with other securities showing similar institutional activity or recent accumulation across several tracked institutions.